MoonLake Immunotherapeutics (MLTX)

Currency in USD
16.38
+0.27(+1.68%)
Closed·
16.52+0.14(+0.85%)
·
Earnings results expected in 6 days
MLTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.0716.66
52 wk Range
5.9562.75
Key Statistics
Prev. Close
16.38
Open
16.33
Day's Range
16.07-16.66
52 wk Range
5.95-62.75
Volume
569.05K
Average Volume (3m)
1.14M
1-Year Change
-61.7158%
Book Value / Share
4.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MLTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
26.71
Upside
+63.09%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

12 Buy
2 Hold
2 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 26.71
(+63.09% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy40.00+144.20%-MaintainApr 15, 2026
Cantor Fitzgerald
Buy---MaintainMar 31, 2026
BTIG
Buy30.00+83.15%-MaintainMar 30, 2026
Wolfe Research
Buy24.00+46.52%12.00UpgradeMar 23, 2026
Rothschild Redburn
Buy40.00+144.20%12.00UpgradeMar 19, 2026

MoonLake Immunotherapeutics SWOT Analysis


Pipeline Progress
Explore MoonLake's clear product development timeline, offering transparency and potential catalysts for growth in the competitive biopharmaceutical landscape
Financial Challenges
Delve into MoonLake's financial health, balancing strong cash positions against projected losses and the implications for future growth and investor confidence
Market Dynamics
Learn how MoonLake navigates a competitive market, with analyst price targets ranging from $65 to $104 amidst anticipated rival product launches
Industry Potential
Discover the positive outlook for the biopharmaceutical sector, presenting opportunities for MoonLake to capitalize on unmet medical needs and technological advancements
Read full SWOT analysis

Earnings

Latest Release
Feb 22, 2026
EPS / Forecast
-0.93 / -0.99
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

MLTX Income Statement

Compare MLTX to Peers and Sector

Metrics to compare
MLTX
Peers
Sector
Relationship
P/E Ratio
−5.2x−3.8x−0.5x
PEG Ratio
0.06−0.240.00
Price/Book
3.9x2.1x2.6x
Price / LTM Sales
-5.1x3.2x
Upside (Analyst Target)
69.0%167.9%48.8%
Fair Value Upside
Unlock1.6%6.9%Unlock

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
3.95M5.50%63.56M
Other Institutional Investors
72.58M94.50%1.17B
Public Companies & Retail Investors
0.000.00%0.00
Total
76.53M100.00%1.23B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BVF Partners L.P.22.31%16,001,284262,101
Biotechnology Value Fund L.P.11.58%8,302,735135,999

People Also Watch

6.390
TSHA
+1.91%
24.000
ENI
+1.50%
9.88
ORIC
+4.66%
14.330
VOR
+2.14%
87.80
DNTH
+5.15%

FAQ

What Is the MoonLake Immunotherapeutics (MLTX) Stock Price Today?

The MoonLake Immunotherapeutics stock price today is 16.38 USD.

What Stock Exchange Does MoonLake Immunotherapeutics Trade On?

MoonLake Immunotherapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for MoonLake Immunotherapeutics?

The stock symbol for MoonLake Immunotherapeutics is "MLTX."

What Is the MoonLake Immunotherapeutics Market Cap?

As of today, MoonLake Immunotherapeutics market cap is 1.17B USD.

What Is MoonLake Immunotherapeutics's Earnings Per Share (TTM)?

The MoonLake Immunotherapeutics EPS (TTM) is -3.53.

When Is the Next MoonLake Immunotherapeutics Earnings Date?

MoonLake Immunotherapeutics will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is MLTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has MoonLake Immunotherapeutics Stock Split?

MoonLake Immunotherapeutics has split 0 times.

How Many Employees Does MoonLake Immunotherapeutics Have?

MoonLake Immunotherapeutics has 130 employees.

What is the current trading status of MoonLake Immunotherapeutics (MLTX)?

As of May 01, 2026, MoonLake Immunotherapeutics (MLTX) is trading at a price of 16.38 USD, with a previous close of 16.38 USD. The stock has fluctuated within a day range of 16.07 USD to 16.66 USD, while its 52-week range spans from 5.95 USD to 62.75 USD.

What Is MoonLake Immunotherapeutics (MLTX) Price Target According to Analysts?

The average 12-month price target for MoonLake Immunotherapeutics is 26.71 USD, with a high estimate of 40 USD and a low estimate of 6 USD. 12 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +63.09% Upside potential.

What Is the MLTX Premarket Price?

MLTX's last pre-market stock price is 16.52 USD. The pre-market share volume is 750.00, and the stock has decreased by 0.14, or 0.85%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.